Logotype for Esprinet S.p.A

Esprinet (PRT) Q2 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Esprinet S.p.A

Q2 2025 earnings summary

8 Jul, 2026

Executive summary

  • H1 2025 sales reached €1,931.5M, up 4% year-over-year, with Q2 sales at €969.1M, up 5% from Q2 2024.

  • Adjusted EBITDA for H1 was €25.1M (+2% YoY), and net income was €3.4M (+5% YoY); Q2 net income rose to €2.9M from €54K in Q2 2024.

  • Strong performance in V-Valley (digital/cloud/cybersecurity) with 12% H1 sales growth and Zeliatech (green tech) with 26% Q2 growth.

  • The Group outperformed the Italian market and saw strong growth in Iberia and Portugal, with a focus on high-margin segments and cost optimisation.

  • Strategic focus on higher-margin businesses, especially solutions, services, and green tech, is yielding results.

Financial highlights

  • Gross profit for H1 was €110.9M (+6% YoY), with a margin of 5.74% (vs. 5.67% in H1 2024); Q2 margin at 5.83%.

  • Adjusted EBITDA: €25.1M (+2% YoY); Q2 EBITDA up 38% YoY.

  • EBIT for H1 was €12.9M (-8% YoY), impacted by higher depreciation from new warehouse investment.

  • Net financial position was negative €327.5M as of June 30, 2025, mainly due to working capital and lease liabilities.

  • ROCE at 6.6% (7.1% as of June 30, 2024).

Outlook and guidance

  • 2025 adjusted EBITDA expected between €63M and €71M, with optimism for the upper end of the range.

  • Revenue growth accelerated in July and August, especially in Iberia and Italy.

  • Focus remains on high-margin segments (V-Valley, Zeliatech) and cost optimization.

  • Industry analysts expect low- to mid-single-digit growth in the ICT distribution market for H2 2025, with Spain outperforming Italy.

  • Continued investment in high-growth segments and potential M&A in green tech.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Esprinet